Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Obesity Rises Among US Women
June 08, 2016 – AJMC Staff
Aggressive Cancer Care Widely Used Among Patients at the End of Life
June 07, 2016 – Cate Douglass
The Value of a 21-Gene Test in Early-Stage Breast Cancer
June 07, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Opioid Restrictions Hurt Those Who Need the Drugs Most
June 07, 2016 – AJMC Staff
ASCO's TAPUR Study Continues to Grow
June 07, 2016 – Cate Douglass
What We're Reading: Biden Will Announce Launch of Open-Access Cancer Database
June 06, 2016 – AJMC Staff
Sitagliptin Does Not Increase Heart Failure Risk for Patients With T2D
June 05, 2016 – Jackie Syrop
AJMC in the Press, June 3, 2016
June 03, 2016
Study Associates High BMI With Risk of Aggressive Prostate Cancer
June 03, 2016 – Surabhi Dangi-Garimella, PhD

What We're Reading: Obesity Rises Among US Women

AJMC Staff
What we're reading, June 8, 2016: obesity rate among women reaches record high; abuse-resistant opioid recommended for approval by advisory panel; and Gilead does not owe Merck money in drug-patent dispute.
The rate of obesity among women in the United States has reached a record high. According to STAT, 40% of women in the US are obese compared with 35% of men. While the population of overweight men and women usually changes at the same rate, between 2013 and 2014 the rate of obesity among women rose, but did not among men. In addition, the rate of obesity among teenagers has doubled in a generation. However, obesity among preschoolers is down.

Teva’s abuse-resistant opioid has received a recommendation for approval by an FDA advisory panel. The long-acting painkiller is designed for patients with pain severe enough that it requires around-the-clock treatment, according to Reuters. The drug will reduce, though not prevent, abuse, and the advisory panel recommended it be approved by a 14-3 vote. While the abuse-deterrent properties are small, they are an improvement over existing painkillers, the panel members determined.

Gilead Sciences Inc. will not have to pay Merck & Co. over a drug-patent dispute. A judge has reversed a jury decision after determining Merck’s attorney involved with obtaining patents for hepatitis C drugs engaged in misconduct, reported The Wall Street Journal. In March, a jury had ordered Gilead to pay $200 million after it found Gilead’s hepatitis C drugs, Sovaldi and Harvoni, infringed upon valid patents held by Merck and Ionis Pharmaceuticals Inc.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up